Machine learning-based model for prediction of clinical deterioration in hospitalized patients by COVID 19.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
received:
18
08
2021
accepted:
29
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
6
5
2022
Statut:
epublish
Résumé
Despite the publication of great number of tools to aid decisions in COVID-19 patients, there is a lack of good instruments to predict clinical deterioration. COVID19-Osakidetza is a prospective cohort study recruiting COVID-19 patients. We collected information from baseline to discharge on: sociodemographic characteristics, comorbidities and associated medications, vital signs, treatment received and lab test results. Outcome was need for intensive ventilatory support (with at least standard high-flow oxygen face mask with a reservoir bag for at least 6 h and need for more intensive therapy afterwards or Optiflow high-flow nasal cannula or noninvasive or invasive mechanical ventilation) and/or admission to a critical care unit and/or death during hospitalization. We developed a Catboost model summarizing the findings using Shapley Additive Explanations. Performance of the model was assessed using area under the receiver operating characteristic and prediction recall curves (AUROC and AUPRC respectively) and calibrated using the Hosmer-Lemeshow test. Overall, 1568 patients were included in the derivation cohort and 956 in the (external) validation cohort. The percentages of patients who reached the composite endpoint were 23.3% vs 20% respectively. The strongest predictors of clinical deterioration were arterial blood oxygen pressure, followed by age, levels of several markers of inflammation (procalcitonin, LDH, CRP) and alterations in blood count and coagulation. Some medications, namely, ATC AO2 (antiacids) and N05 (neuroleptics) were also among the group of main predictors, together with C03 (diuretics). In the validation set, the CatBoost AUROC was 0.79, AUPRC 0.21 and Hosmer-Lemeshow test statistic 0.36. We present a machine learning-based prediction model with excellent performance properties to implement in EHRs. Our main goal was to predict progression to a score of 5 or higher on the WHO Clinical Progression Scale before patients required mechanical ventilation. Future steps are to externally validate the model in other settings and in a cohort from a different period and to apply the algorithm in clinical practice.Registration: ClinicalTrials.gov Identifier: NCT04463706.
Identifiants
pubmed: 35501359
doi: 10.1038/s41598-022-09771-z
pii: 10.1038/s41598-022-09771-z
pmc: PMC9059444
doi:
Substances chimiques
Oxygen
S88TT14065
Banques de données
ClinicalTrials.gov
['NCT04463706']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7097Investigateurs
Susana García-Gutiérrez
(S)
Iratxe Lafuente
(I)
Jose María Quintana
(JM)
Miren Orive
(M)
Nerea Gonzalez
(N)
Ane Anton
(A)
Ane Villanueva
(A)
Cristina Muñoz
(C)
Maria Jose Legarreta
(MJ)
Raul Quirós
(R)
Pedro Pablo España Yandiola
(PPE)
Mikel Egurrola
(M)
Amaia Aramburu
(A)
Amaia Artaraz
(A)
Leire Chasco
(L)
Olaia Bronte
(O)
Patricia García
(P)
Ana Jodar
(A)
Virginia Fernandez
(V)
Cristobal Esteban
(C)
Naia Mas
(N)
Esther Pulido
(E)
Itxaso Bengoetxea
(I)
Antonio Escobar Martínez
(AE)
Amaia Bilbao
(A)
Iñigo Gorostiza
(I)
Iñaki Arriaga
(I)
José Joaquín Portu Zapiarain
(JJP)
Naiara Parraza
(N)
Milagros Iriberri
(M)
Rafael Zalacain
(R)
Luis Alberto Ruiz
(LA)
Leyre Serrano
(L)
Adriana Couto
(A)
Oier Ateka
(O)
Arantza Cano
(A)
Maria Olatz Ibarra
(MO)
Eduardo Millan
(E)
Mayte Bacigalupe
(M)
Jon Letona
(J)
Andoni Arcelay
(A)
Iñaki Berraondo
(I)
Xavier Castells
(X)
Margarita Posso
(M)
Lilisbeth Perestelo
(L)
Guillermo Perez Acosta
(GP)
Candelaria Martín Gonzñalez
(CM)
Maximino Redondo
(M)
Maria Padilla
(M)
Adolfo Muñoz
(A)
Ricardo Saenz de Madariaga
(RS)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Lancet Respir Med. 2021 Apr;9(4):349-359
pubmed: 33444539
Cardiol J. 2021;28(3):360-368
pubmed: 33843043
BMJ Open Respir Res. 2020 Dec;7(1):
pubmed: 33293361
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Encephale. 2020 Jun;46(3):169-172
pubmed: 32425222
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
J Clin Med. 2020 Jun 01;9(6):
pubmed: 32492874
Gastroenterology. 2021 Jan;160(1):455-458.e5
pubmed: 32980342
J Clin Pharmacol. 2021 Oct;61(10):1286-1300
pubmed: 33908637
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32616597
J Comput Aided Mol Des. 2020 Oct;34(10):1013-1026
pubmed: 32361862
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
J Med Internet Res. 2020 Oct 28;22(10):e21801
pubmed: 33090964
JAMA Netw Open. 2020 Sep 1;3(9):e2022058
pubmed: 32965501
PLoS One. 2020 Nov 18;15(11):e0241541
pubmed: 33206661
Clin Microbiol Infect. 2021 Jul;27(7):1040.e7-1040.e10
pubmed: 33887469
Int J Infect Dis. 2020 Sep;98:84-89
pubmed: 32553714
BMC Infect Dis. 2020 Dec 11;20(1):952
pubmed: 33308159
JAMA. 2020 Nov 24;324(20):2095-2096
pubmed: 33074293